COMPANY

Arcus Biosciences

HQ: Hayward, CA source · arcusbio.com ↗ · West Coast

Location: Hayward, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Non Small Cell Lung Cancer Ovarian Cancer Nonsquamous Non Small Cell Lung Cancer Squamous Non Small Cell Lung Cancer Lung Cancer Bladder Cancer Cervical Cancer Esophageal Cancer Gastric Cancer Non-Small Cell Lung Cancer Melanoma Castration-Resistant Prostatic Neoplasms GastroEsophageal Cancer Colorectal Cancer Clear Cell Renal Cell Carcinoma Gastroesophageal-junction Cancer Head and Neck Squamous Cell Carcinoma Renal Cell Carcinoma Triple Negative Breast Cancer Metastatic Pancreatic Ductal Adenocarcinoma Metastatic Clear Cell Renal Cell Carcinoma Advanced Clear Cell Renal Cell Carcinoma Gastrointestinal Tract Malignancies Advanced Pancreatic Cancer Hepatic Impairment Advanced Upper Gastrointestinal Tract Adenocarcinoma Metastatic Colorectal Cancer Multiple Myeloma Non-Hodgkin Lymphoma Diffuse Large B Cell Lymphoma Gastroesophageal Junction Adenocarcinoma Androgen-Resistant Prostatic Neoplasms Castration-Resistant Prostatic Cancer Solid Tumor, Unspecified, Adult Non Small Cell Lung Cancer Metastatic Nonsquamous Nonsmall Cell Neoplasm of Lung Sensitizing EGFR Gene Mutation Squamous Cell Carcinoma of the Head and Neck

32Trials (company is sponsor)

Timeline

Aug 14, 2026 Trial start Phase 1: Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function source ↗
Jul 9, 2026 Trial start Phase 1: A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants source ↗
May 29, 2026 Trial start Phase 1: A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants source ↗
Feb 3, 2026 Trial start Phase 1: Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) source ↗
Sep 8, 2025 Trial start Phase 3: Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma source ↗
May 2, 2025 Trial start Phase 1: Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29) source ↗
Dec 13, 2024 Trial start Phase 3: Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma source ↗
Jan 19, 2024 Trial start Phase 1: A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies source ↗
Oct 16, 2023 Trial start Phase 1: A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers source ↗
Oct 13, 2023 Trial start Phase 1: Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers source ↗
Aug 21, 2023 Trial start Phase 1: A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers source ↗
Nov 21, 2022 Trial start Phase 3: A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery T source ↗
Oct 26, 2022 Trial start 1: A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors source ↗
Jun 10, 2022 Trial start Phase 2: A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies source ↗
May 25, 2022 Trial start Phase 1: A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer source ↗
Feb 10, 2022 Trial start Phase 1: A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants source ↗
Nov 9, 2021 Trial start Phase 1: Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers source ↗
Oct 20, 2021 Trial start Phase 1: A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants source ↗
May 10, 2021 Trial start Phase 1/Phase 2: An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. source ↗
Mar 19, 2021 Trial start Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies source ↗
Feb 8, 2021 Trial start Phase 2: Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer source ↗
Oct 20, 2020 Trial start Phase 1: A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers source ↗
Jul 7, 2020 Trial start Phase 1/Phase 2: Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer source ↗
May 28, 2020 Trial start Phase 2: Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer source ↗
Nov 6, 2019 Trial start Phase 1: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies source ↗

Showing 25 of 32 dated events.

Upcoming milestones

2026-12 (ESTIMATED) · Phase 1 · A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants · NCT07662057
2027-01 (ESTIMATED) · Phase 2 · A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies · NCT05329766
2027-05 (ESTIMATED) · Phase 2 · Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer · NCT04736173
2027-05 (ESTIMATED) · Phase 1 · Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function · NCT07751250
2027-09 (ESTIMATED) · Phase 1 · Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers · NCT05891171
2028-04 (ESTIMATED) · Phase 3 · Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma · NCT07011719
2029-03 (ESTIMATED) · 1 · A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors · NCT05536141
Nov 30, 2030 (ESTIMATED) · Phase 3 · Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma · NCT06608927

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 32

Record	Title	Phase	Status	Start	Primary completion
NCT06120075	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies	Phase 1	Completed	Jan 19, 2024	Apr 29, 2026 (actual)
NCT04736173	Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer	Phase 2	Active, not recruiting	Feb 8, 2021	2027-05 (estimated)
NCT05536141	A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors	1	Recruiting	Oct 26, 2022	2029-03 (estimated)
NCT05891171	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers	Phase 1	Active, not recruiting	Oct 13, 2023	2027-09 (estimated)
NCT06608927	Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Active, not recruiting	Dec 13, 2024	Nov 30, 2030 (estimated)
NCT07011719	Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma	Phase 3	Recruiting	Sep 8, 2025	2028-04 (estimated)
NCT05329766	A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies	Phase 2	Active, not recruiting	Jun 10, 2022	2027-01 (estimated)
NCT04104672	A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies	Phase 1	Completed	Nov 6, 2019	Jul 21, 2026 (actual)
NCT07751250	Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function	Phase 1	Recruiting	Aug 14, 2026	2027-05 (estimated)
NCT05568095	A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body	Phase 3	Completed	Nov 21, 2022	Aug 28, 2026 (actual)
NCT07662057	A Study to Investigate the Safety, Tolerability, and PK of AB102 in Healthy Participants	Phase 1	Recruiting	Jul 9, 2026	2026-12 (estimated)
NCT07641881	A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants	Phase 1	Completed	May 29, 2026	Jul 3, 2026 (actual)
NCT04262856	Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer	Phase 2	Completed	May 28, 2020	Jul 9, 2025 (actual)
NCT07364214	Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)	Phase 1	Completed	Feb 3, 2026	Apr 6, 2026 (actual)
NCT06919991	Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)	Phase 1	Completed	May 2, 2025	Oct 18, 2025 (actual)
NCT04660812	An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.	Phase 1/Phase 2	Completed	May 10, 2021	Sep 5, 2025 (actual)
NCT04772989	A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	Phase 1	Completed	Mar 19, 2021	Aug 25, 2025 (actual)
NCT04381832	Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer	Phase 1/Phase 2	Completed	Jul 7, 2020	Aug 30, 2024 (actual)
NCT03628677	A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies	Phase 1	Completed	Sep 12, 2018	Jan 23, 2025 (actual)
NCT03846310	A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer	Phase 1	Completed	Apr 1, 2019	Nov 18, 2024 (actual)
NCT05117554	Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers	Phase 1	Completed	Nov 9, 2021	Feb 17, 2023 (actual)
NCT05999513	A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers	Phase 1	Completed	Aug 21, 2023	Oct 31, 2023 (actual)
NCT04087018	Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors	Phase 1	Completed	Sep 24, 2019	Jun 17, 2024 (actual)
NCT06004921	A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers	Phase 1	Completed	Oct 16, 2023	Feb 23, 2024 (actual)
NCT04575311	A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers	Phase 1	Completed	Oct 20, 2020	Sep 22, 2021 (actual)
NCT03720678	A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies	Phase 1	Completed	Nov 18, 2018	Jan 27, 2021 (actual)
NCT05154136	A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants	Phase 1	Completed	Oct 20, 2021	Dec 10, 2021 (actual)
NCT03629756	A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies	Phase 1	Completed	Jul 24, 2018	Aug 18, 2021 (actual)
NCT03677973	A Study to Investigate the Safety of AB680 in Healthy Volunteers	Phase 1	Completed	Oct 16, 2018	Aug 19, 2019 (actual)
NCT05411146	A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer	Phase 1	Completed	May 25, 2022	Jul 7, 2022 (actual)
NCT03719326	A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies	Phase 1	Completed	Oct 15, 2018	Jul 1, 2021 (actual)
NCT05277012	A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants	Phase 1	Completed	Feb 10, 2022	Mar 31, 2022 (actual)